72. Pituitary ADH secretion disorder Clinical trials / Disease details
Clinical trials : 40 / Drugs : 28 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04902235 (ClinicalTrials.gov) | July 6, 2021 | 17/5/2021 | Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study) | Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept Physiopathological Study (CRH Study) | Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin Deficiency | Drug: Experimental: CRH administration;Drug: Control: Placebo administration | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Instituto de Salud Carlos III | Recruiting | 18 Years | 65 Years | All | 52 | Phase 4 | Spain |